title: Repeat prostate biopsy: who, how and when?. a review.
abstract: Urologists are frequently faced with the dilemma of treating a patient with a high index of suspicion of prostate cancer (PCa), but an initial set of negative biopsies. In this review, we evaluated the current knowledge on repeat prostate biopsies, focusing on when to perform them and in which patients, how many samples to take, where to direct the biopsies and what morbidity should be expected. We focussed on the available literature and the multicenter European Prostate Cancer Detection (EPCD) study. The EPCD study included 1051 men with a total PSA from 4 to 10 ng/ml who underwent a transrectal ultrasound (TRUS) guided sextant biopsy and a repeat biopsy in case of a negative initial biopsy. Most studies support that increasing the number of biopsy cores as compared to the sextant technique and improving prostate peripheral zone (PZ) sampling result in a significant improvement in the detection of prostate cancer without increase in morbidity or effects on quality of life. Re-biopsy can be performed 6 weeks later with no significant difference in pain or morbidity. At least 10% of patients with negative sextant prostatic biopsy results in the EPCD study were diagnosed with PCa on repeat biopsy, percent free PSA and PSA density of the transition zone being the most accurate predictors. Despite differences in location (more apico-dorsal) and multifocality, pathological and biochemical features of cancers detected on initial and repeat biopsy were similar, suggesting similar biological behavior and thus advocating for a repeat prostate biopsy in case of a negative finding on initial biopsy. Indications and ideal number of biopsy cores to take when repeating biopsies in patients who already underwent extensive biopsy protocols on the first biopsy remains to be determined.
authors.affiliation: Department of Urology, University of Vienna, Vienna, Austria.
authors.forename: Bob
authors.initials: B
authors.lastname: Djavan
authors.forename: Mesut
authors.initials: M
authors.lastname: Remzi
authors.forename: Claude C
authors.initials: CC
authors.lastname: Schulman
authors.forename: Michael
authors.initials: M
authors.lastname: Marberger
authors.forename: Alexandre R
authors.initials: AR
authors.lastname: Zlotta
mesh_terms: D001706:Biopsy / Q000379:methods* / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000473:pathology*; D012680:Sensitivity and Specificity
chemical_list: D017430:Prostate-Specific Antigen